Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02278796 | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)(BEB) | completed | Phase 2 | 108 | Insel Gruppe AG, University Hospital BernOTHER | 2 | Aug 1, 2025 | clinicaltrials |
| NCT03013218 | A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) | completed | Phase 1 | 174 | ALX Oncology Inc.INDUSTRY | 2 | Aug 1, 2025 |
| clinicaltrials |
| NCT05964322 | Cardiac Rehabilitation of Children and Adolescent With Long QT Syndrome(RYTHMO'FIT) | completed | — | 8 | University Hospital, MontpellierOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06163040 | A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | completed | — | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03496779 | Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | completed | Phase 2 | 71 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 30, 2025 | clinicaltrials |
| NCT03548207 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma(CARTITUDE-1) | completed | Phase 1 / Phase 2 | 126 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT04994158 | MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis(MASCOT-R) | completed | — | 238 | Royal Free Hospital NHS Foundation TrustOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05419648 | Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)(MonSThr) | completed | — | 68 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05499611 | Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia(COALA) | completed | — | 120 | University Hospital, BordeauxOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04621851 | Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation | completed | — | 260 | University of Milano BicoccaOTHER | 4 | Jul 29, 2025 | clinicaltrials |
| NCT05391022 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | completed | Phase 1 | 35 | Constellation PharmaceuticalsINDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT06041698 | Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma | completed | N/A | 62 | Thomas Jefferson UniversityOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05049785 | Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone | completed | Early Phase 1 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT01385423 | Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT01864018 | Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | completed | Phase 1 / Phase 2 | 87 | Mayo ClinicOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04813653 | Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells | completed | Phase 1 | 3 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 24, 2025 | clinicaltrials |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 25 | University of MiamiOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05506982 | Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain | completed | Phase 1 | 11 | Emory UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05549232 | Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital | completed | — | 22 | HemanextINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05583318 | Living Conditions After Non-Hodgkin's Lymphoma in France(LymphoVie 2) | completed | — | 1,570 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06602674 | PET/CT-Based Image Analysis and Machine Learning of Hypermetabolic Pulmonary Lesions | completed | — | 647 | Ruijin HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06659224 | The Risk of Acute Myeloid Leukaemia in Patients With Ewing's Sarcoma | completed | — | 2,631 | asmaa salama ibrahimOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)(SYMPATICO) | completed | Phase 3 | 366 | Pharmacyclics LLC.INDUSTRY | 17 | Jul 22, 2025 | clinicaltrials |
| NCT06592846 | FERtility After Therapy With Intensive Lymphoma in Young Women: LNH-03 1B, LNH-03 2B, LNH-07 3B, GAINED Follow-up(FERTILE) | completed | — | 80 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05011097 | A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 20 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05444530 | A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms | completed | Phase 1 | 14 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 20, 2025 | clinicaltrials |
| NCT06061302 | Multiple Myeloma Yoga Pilot Study | completed | N/A | 31 | University of ArizonaOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02956382 | Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 24 | Georgetown UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT01051635 | A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02763319 | A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)(B-MIND) | completed | Phase 2 / Phase 3 | 453 | Incyte CorporationINDUSTRY | 23 | Jul 17, 2025 | clinicaltrials |
| NCT05236296 | Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study(EASE-CG) | completed | N/A | 40 | University Health Network, TorontoOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04833504 | Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma | completed | — | 39 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05662956 | A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | completed | Phase 2 | 114 | Hematology department of the 920th hospitalOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT05019144 | Telemedicine Optimized Burn Intervention(TOBI) | completed | N/A | 130 | Medical University of South CarolinaOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT01996865 | Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.(MAGNIFY) | completed | Phase 3 | 503 | CelgeneINDUSTRY | 3 | Jul 10, 2025 | clinicaltrials |
| NCT04827446 | Lighting Intervention for Cancer-related Fatigue | completed | N/A | 139 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT00812669 | CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | completed | Phase 2 | 52 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission(QUAZAR AML-001) | completed | Phase 3 | 472 | CelgeneINDUSTRY | 23 | Jul 8, 2025 | clinicaltrials |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 523 | Janssen Research & Development, LLCINDUSTRY | 28 | Jul 8, 2025 | clinicaltrials |
| NCT02329080 | New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement | completed | Phase 2 | 79 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Jul 8, 2025 | clinicaltrials |
| NCT04589728 | Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 | completed | — | 202 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT04618081 | Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) | completed | — | 151 | CelgeneINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04669210 | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT(PTCyRuxo) | completed | Phase 2 | 128 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06511869 | AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) | completed | Phase 2 | 48 | Dizal PharmaceuticalsINDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04827745 | Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL | completed | Phase 2 | 2 | University of Maryland, BaltimoreOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03884556 | TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers | completed | Phase 1 | 56 | Trishula Therapeutics, Inc.INDUSTRY | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02821793 | Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer(PRIORITY) | completed | — | 346 | Institut BergoniéOTHER | 1 | Jul 1, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Aug 1, 2025source: clinicaltrials